Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials
Marit Vermunt,1 Serena Marchetti,2 Jos Beijnen1,3,4 1Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066, CX, the Netherlands; 2Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066, CX, the Netherlands; 3Modra Pharmaceutica...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-01-01
|
| Series: | Clinical Pharmacology: Advances and Applications |
| Subjects: | |
| Online Access: | https://www.dovepress.com/pharmacokinetics-and-toxicities-of-oral-docetaxel-formulations-co-admi-peer-reviewed-article-CPAA |
| _version_ | 1818432590469660672 |
|---|---|
| author | Vermunt M Marchetti S Beijnen J |
| author_facet | Vermunt M Marchetti S Beijnen J |
| author_sort | Vermunt M |
| collection | DOAJ |
| description | Marit Vermunt,1 Serena Marchetti,2 Jos Beijnen1,3,4 1Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066, CX, the Netherlands; 2Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066, CX, the Netherlands; 3Modra Pharmaceuticals B.V., Amsterdam 1083, HN, the Netherlands; 4Department of Pharmaceutical Sciences, Utrecht University, Utrecht 3584, CX, the NetherlandsCorrespondence: Marit VermuntDepartment of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066, CX, the NetherlandsTel +31 20 512 2127Fax +31 20 512 4753Email m.vermunt@nki.nlIntroduction: Docetaxel is widely used as intravenous (IV) chemotherapy. Oral docetaxel is co-administered with the cytochrome P450 3A4 and P-glycoprotein inhibitor ritonavir to increase oral bioavailability. This research explores the relationship between the pharmacokinetics (PK) and toxicity of this novel oral chemotherapy.Methods: The patients in two phase I trials were treated with different oral docetaxel formulations in combination with ritonavir in different dose levels, ranging from 20 to 80 mg docetaxel with 100 to 200 mg ritonavir a day. The patients were categorized based on the absence or occurrence of severe treatment-related toxicity (grade ≥ 3 or any grade leading to treatment alterations). The docetaxel area under the plasma concentration–time curve (AUC) and maximum plasma concentration (Cmax) were associated with toxicity.Results: Thirty-four out of 138 patients experienced severe toxicity, most frequently observed as mucositis, fatigue, diarrhea, nausea and vomiting. The severe toxicity group had a significantly higher docetaxel AUC (2231 ± 1405 vs 1011 ± 830 ng/mL*h, p< 0.0001) and Cmax (218 ± 178 vs 119 ± 77 ng/mL, p< 0.0001) as compared to the patients without severe toxicity. When extrapolated from IV PK data, the patients without severe toxicity had a similar cumulative docetaxel AUC as with standard 3-weekly IV docetaxel, while the Cmax was up to 10-fold lower with oral docetaxel and ritonavir.Conclusion: Severe toxicity was observed in 25% of the patients treated with oral docetaxel and ritonavir. This toxicity seems related to the PK, as the docetaxel AUC0-inf and Cmax were up to twofold higher in the severe toxicity group as compared to the non-severe toxicity group. Future randomized trials will provide a further evaluation of the toxicity and efficacy of the new weekly oral docetaxel and ritonavir regimen in comparison to standard IV docetaxel.Keywords: oral docetaxel, ritonavir, pharmacokinetics, toxicity |
| first_indexed | 2024-12-14T16:07:37Z |
| format | Article |
| id | doaj.art-091def07b27d48a1b852653d790f61e6 |
| institution | Directory Open Access Journal |
| issn | 1179-1438 |
| language | English |
| last_indexed | 2024-12-14T16:07:37Z |
| publishDate | 2021-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Pharmacology: Advances and Applications |
| spelling | doaj.art-091def07b27d48a1b852653d790f61e62022-12-21T22:55:02ZengDove Medical PressClinical Pharmacology: Advances and Applications1179-14382021-01-01Volume 13213261543Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I TrialsVermunt MMarchetti SBeijnen JMarit Vermunt,1 Serena Marchetti,2 Jos Beijnen1,3,4 1Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066, CX, the Netherlands; 2Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066, CX, the Netherlands; 3Modra Pharmaceuticals B.V., Amsterdam 1083, HN, the Netherlands; 4Department of Pharmaceutical Sciences, Utrecht University, Utrecht 3584, CX, the NetherlandsCorrespondence: Marit VermuntDepartment of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066, CX, the NetherlandsTel +31 20 512 2127Fax +31 20 512 4753Email m.vermunt@nki.nlIntroduction: Docetaxel is widely used as intravenous (IV) chemotherapy. Oral docetaxel is co-administered with the cytochrome P450 3A4 and P-glycoprotein inhibitor ritonavir to increase oral bioavailability. This research explores the relationship between the pharmacokinetics (PK) and toxicity of this novel oral chemotherapy.Methods: The patients in two phase I trials were treated with different oral docetaxel formulations in combination with ritonavir in different dose levels, ranging from 20 to 80 mg docetaxel with 100 to 200 mg ritonavir a day. The patients were categorized based on the absence or occurrence of severe treatment-related toxicity (grade ≥ 3 or any grade leading to treatment alterations). The docetaxel area under the plasma concentration–time curve (AUC) and maximum plasma concentration (Cmax) were associated with toxicity.Results: Thirty-four out of 138 patients experienced severe toxicity, most frequently observed as mucositis, fatigue, diarrhea, nausea and vomiting. The severe toxicity group had a significantly higher docetaxel AUC (2231 ± 1405 vs 1011 ± 830 ng/mL*h, p< 0.0001) and Cmax (218 ± 178 vs 119 ± 77 ng/mL, p< 0.0001) as compared to the patients without severe toxicity. When extrapolated from IV PK data, the patients without severe toxicity had a similar cumulative docetaxel AUC as with standard 3-weekly IV docetaxel, while the Cmax was up to 10-fold lower with oral docetaxel and ritonavir.Conclusion: Severe toxicity was observed in 25% of the patients treated with oral docetaxel and ritonavir. This toxicity seems related to the PK, as the docetaxel AUC0-inf and Cmax were up to twofold higher in the severe toxicity group as compared to the non-severe toxicity group. Future randomized trials will provide a further evaluation of the toxicity and efficacy of the new weekly oral docetaxel and ritonavir regimen in comparison to standard IV docetaxel.Keywords: oral docetaxel, ritonavir, pharmacokinetics, toxicityhttps://www.dovepress.com/pharmacokinetics-and-toxicities-of-oral-docetaxel-formulations-co-admi-peer-reviewed-article-CPAAoral docetaxelritonavirpharmacokineticstoxicity |
| spellingShingle | Vermunt M Marchetti S Beijnen J Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials Clinical Pharmacology: Advances and Applications oral docetaxel ritonavir pharmacokinetics toxicity |
| title | Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials |
| title_full | Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials |
| title_fullStr | Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials |
| title_full_unstemmed | Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials |
| title_short | Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials |
| title_sort | pharmacokinetics and toxicities of oral docetaxel formulations co administered with ritonavir in phase i trials |
| topic | oral docetaxel ritonavir pharmacokinetics toxicity |
| url | https://www.dovepress.com/pharmacokinetics-and-toxicities-of-oral-docetaxel-formulations-co-admi-peer-reviewed-article-CPAA |
| work_keys_str_mv | AT vermuntm pharmacokineticsandtoxicitiesoforaldocetaxelformulationscoadministeredwithritonavirinphaseitrials AT marchettis pharmacokineticsandtoxicitiesoforaldocetaxelformulationscoadministeredwithritonavirinphaseitrials AT beijnenj pharmacokineticsandtoxicitiesoforaldocetaxelformulationscoadministeredwithritonavirinphaseitrials |